Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.

The presence of apolipoprotein E-epsilon4 (APOE-epsilon4) allele has been implicated as a risk factor for Alzheimer's disease (AD). We examined the frequencies of APOE-epsilon4 alleles in age-matched controls and subgroups of 190 AD subjects exhibited cerebral amyloid angiopathy (CAA) and other frequently associated lesions. CAA was evident in 96% of the AD subjects, which were divided into two groups, one bearing mild or no apparent CAA and the other with moderate to severe CAA. APOE-epsilon4 allele frequency (48%) in the latter advanced CAA group was six times higher than in those who exhibited mild CAA. In the advanced CAA subjects, the occurrence of an epsilon4 allele was increased by a factor of 17 (95% confidence interval, 7.56 to 38.9). This was despite the fact that neocortical amyloid-beta plaque densities in the two groups were similar and that all of the AD subjects had met the accepted neuropathological criteria. We also observed that the degree of CAA severity was greatest in the group of subjects with the epsilon4/epsilon4 genotype. The association between CAA and APOE-epsilon4 was further implicated in two non-AD subjects among neurological controls with severe CAA. These two subjects, both homozygous for the APOE-epsilon4 allele, were primarily diagnosed as having Creutzfeldt-Jakob disease and Pick's disease in the absence of significant neocortical amyloid deposition. Allele frequency comparisons between neurological control subjects with CAA and those without likewise accorded a strong relationship between the APOE-epsilon4 allele and the presence of CAA. More remarkably, the epsilon4 allele frequency was highly associated with AD subjects exhibiting lobar or intracerebral hemorrhage, all of whom had advanced CAA. We observed that 36% of the AD subjects had concomitant cerebrovascular pathology resulting from single infarcts, multiple microinfarcts, ischemic white matter lesions, or petechial hemorrhages. Although the difference in APOE genotype distribution between subjects with and without cerebrovascular lesions did not reach statistical significance, we did note that the frequency of the epsilon4 allele was significantly higher in subjects with such pathology as compared with those without. However, we found no evidence to suggest that the acquisition of an APOE-epsilon4 allele or one of the alleles, epsilon2 or epsilon3, was a factor in the occurrence of atherosclerosis localized in the basal surface arteries. Analyses of our sample also confirm that there was a lower frequency of the APOE-epsilon2 allele in AD subjects and that the frequency of the epsilon4 allele in AD subjects with concomitant diffuse Lewy body disease was intermediate between controls and AD subjects. Our results suggest that the APOE-epsilon4 allele is a significant factor in the development of CAA in AD and reveal the possibility that APOE is an independent factor in CAA and other vascular abnormalities associated with AD.

[1]  H. Soininen,et al.  Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. , 1995, Stroke.

[2]  P. Hedera,et al.  Differential degeneration of the cerebral microvasculature in Alzheimer's disease. , 1995, Neuroreport.

[3]  E. Perry,et al.  Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. , 1994, The American journal of pathology.

[4]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[5]  M. Pericak-Vance,et al.  Apolipoprotein E in Creutzfeldt-Jakob disease , 1995, The Lancet.

[6]  C. van Broeckhoven,et al.  The apolipoprotein E ε4 allele does not influence the clinical expression of the amyloid precursor protein gene codon 693 or 692 mutations , 1994, Annals of neurology.

[7]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[8]  R. Kalaria,et al.  Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. , 1993, The American journal of pathology.

[9]  N. Craddock,et al.  Protection against Alzheimer's disease with apoE ∈2 , 1994, The Lancet.

[10]  PhilipR. Wenham,et al.  Apolipoprotein E genotyping by one-stage PCR , 1991, The Lancet.

[11]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[12]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Amouyel,et al.  The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease , 1994, The Lancet.

[14]  D. Graham,et al.  Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury , 1995, Nature Medicine.

[15]  J. Vonsattel,et al.  Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study , 1991, Annals of neurology.

[16]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[17]  R. Lipton,et al.  Amyloid angiopathy in diffuse Lewy body disease , 1992, Neurology.

[18]  H. Vinters.  Cerebral amyloid angiopathy. A critical review. , 1987, Stroke.

[19]  G. Schellenberg,et al.  Apolipoprotein E genotype and Alzheimer's disease , 1993, The Lancet.

[20]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[21]  Z. Khachaturian.  Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[22]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Pickering-Brown,et al.  Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases , 1994, The Lancet.

[24]  D. Galasko,et al.  Apolipoprotein-E ε-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease , 1994, Neuroscience Letters.

[25]  J. Hardy,et al.  Senile dementia of the Lewy body type has an apolipoprotein E ε4 allele frequency intermediate between controls and Alzheimer's disease , 1994, Neuroscience Letters.

[26]  J. Hardy,et al.  Hereditary cerebral hemorrhage with amyloidosis — Dutch type: its importance for Alzheimer research , 1991, Trends in Neurosciences.

[27]  A. Roses,et al.  Apolipoprotein E genotype and Lewy body disease , 1995, Neurology.

[28]  D. Premkumar,et al.  Altered Expression of Amyloid β Precursor mRNAs in Cerebral Vessels, Meninges, and Choroid Plexus in Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[29]  M. Pericak-Vance,et al.  Apolipoprotein E ∈4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases , 1993, The Lancet.

[30]  T. Mandybur.  Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications , 1986, Journal of neuropathology and experimental neurology.

[31]  R. Kalaria,et al.  Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease , 1992, Brain Research.

[32]  A Brun,et al.  White matter changes in dementia of Alzheimer's type: the difference in vulnerability between cell compartments , 1990, Histopathology.

[33]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[34]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[35]  D. Premkumar,et al.  Apolipoprotein E Alleles and Brain Vascular Pathology in Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[36]  G. Frisoni,et al.  Apolipoprotein E ε4 Allele in Alzheimer's Disease and Vascular Dementia , 1994 .

[37]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[38]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[39]  T. Iwatsubo,et al.  Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease , 1994, The Lancet.

[40]  A. Roses.  Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.

[41]  D. Neary,et al.  Apolipoprotein E allelic frequencies in patients with lobar atrophy , 1995, Neuroscience Letters.

[42]  G. Perry,et al.  Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease , 1993, Brain Research.

[43]  Kalaria Rn,et al.  The blood-brain barrier and cerebral microcirculation in Alzheimer disease. , 1992 .

[44]  M. Pericak-Vance,et al.  Apolipoprotein E E4 allele and risk of dementia. , 1995, JAMA.

[45]  B. Hyman,et al.  Frequency of the apolipoprotein E ε2 allele is diminished in sporadic Alzheimer disease , 1994, Neuroscience Letters.